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A B S T R A C T
Over 3 years, during six 1-month periods of surveillance, 69 cases of Enterococcus faecium colonisation or
infection were detected in a university hospital in eastern France. Thirty-two cases involved strains
resistant to amoxycillin (crude incidence of 0.21/1000 patient-days). The risk of infection with E. faecium
was higher if the patient was hospitalised in a haematology ward and/or treated with cephalosporins.
Amoxycillin-resistant isolates (AmRE) were isolated from different wards and time periods, and none of
the characteristics studied were associated significantly with amoxycillin resistance. Amoxycillin-
sensitive and -resistant isolates were characterised by pulsed-field gel electrophoresis. Three epidemic
patterns were identified which contained 87.5% (28 ⁄ 32) of the AmRE isolates, indicating that clonal
spread was responsible, at least partially, for the high incidence of AmRE in this hospital.
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I N T R O D U C T I O N
Enterococci are now established firmly as major
nosocomial pathogens. Bacteria of the genus
Enterococcus are the fourth most common cause
of hospital-acquired infection and the third most
common cause of bacteraemia in the USA [1]. The
treatment of choice for these infections is usually
a synergic combination of a penicillin with an
aminoglycoside or a glycopeptide. With the
emergence of strains displaying resistance to
glycopeptides, mostly Enterococcus faecium
(VRE), multiple resistance to all currently
approved antimicrobial agents is now possible
in enterococcal strains [2–4]. Such strains with
multiple resistance have caused major outbreaks
within hospitals in the USA, and have also
transferred from one hospital to another [5–7].
In France, vancomycin resistance in E. faecium
isolates does not seem to be a major problem at
the moment [8–10]. In contrast, a large but
variable proportion of E. faecium isolates has
acquired high-level resistance to aminoglycosides
and resistance to amoxycillin [8–10]. The mean
reported rates of resistance to amoxycillin for
E. faecium hospital isolates in various countries
range from 23.3% to 98.7% [8–11]. Resistance
affects the current treatment of enterococcal infec-
tions. Moreover, in the USA, amoxycillin resist-
ance in E. faecium has been proposed as a risk
factor for the spread of vancomycin resistance,
with the genetic element conferring amoxycillin
resistance being sometimes linked to vancomycin
resistance transposons, such as Tn5382 [12].
In hospitals, the emergence and spread of
resistant pathogens can be limited by improving
management procedures; e.g., by isolating carri-
ers or infected patients to prevent cross-colonisa-
tion, and by implementing antibiotic policies to
reduce the selection of resistant bacteria during
treatment [13]. The efficacy of such strategies to
control resistance depends on the epidemiology
of the resistant bacteria in a given institution [14].
This study reports the rates of infection with
E. faecium and the level of resistance among
isolates from Besanc¸on University Hospital in
eastern France. The epidemiological and micro-
biological characteristics of the amoxycillin-
resistant isolates (AmRE) obtained during the
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six 1-month periods of the survey were deter-
mined.
M A T E R I A L S A N D M E T H O D S
Setting
Besanc¸on Hospital is a public university hospital with 1320
beds in acute care facilities comprising three intensive care
units (ICUs), 16 general medical and 11 surgical wards.
Around 50 000 patients are admitted each year, giving
355 000 patient-days of hospitalisation/year.
Study design
Clinical cultures (excluding stool cultures) from all patients
admitted to the hospital were examined to identify possible
cases of Enterococcus colonisation or infection, in a non-sequen-
tial study (six 1-month periods: November 1995 ¼ A; May
1996 ¼ B; November 1996 ¼ C; May 1997 ¼ D; November
1997 ¼ E; May 1998 ¼ F). Enterococcus isolates were identified
to species level (see below). Amoxycillin-susceptible and am-
oxycillin-resistant E. faecium isolates were characterised by
pulsed-field gel electrophoresis (PFGE). Patients with positive
cultures were compared in two case-control studies to identify
risk factors for colonisation or infection with E. faecium strains,
and for colonisation or infection with amoxycillin-resistant
E. faecium strains.
Bacterial strains
Enterococci were identified to the species level, using the API
20 Strep system (bioMe´rieux, Lyon, France). Standardised disk
diffusion tests were performed to determine susceptibility to
erythromycin, chloramphenicol, co-trimoxazole, tetracycline,
and amoxycillin according to the criteria recommended by the
Antibiogram Committee of the French Society for Microbio-
logy (MIC breakpoints of 4 and 16 mg ⁄L) and the NCCLS
[15,16]. Isolates were tested for b-lactamase production with
nitrocefin. High-level aminoglycoside resistance was detected
by breakpoint screening on Mueller-Hinton agar (MHA; BBL,
Cockeysville, MD) containing kanamycin (1000 mg ⁄L) (HLKR)
or gentamicin (500 mg ⁄L) (HLGR). Such high-level resistance
in clinical enterococcal isolates is usually mediated by various
aminoglycoside-modifying enzymes causing resistance to
amikacin if kanamycin resistance is detected, and to most
commercially available aminoglycosides if gentamicin resist-
ance is detected. The MICs of penicillin, amoxycillin ± clavul-
anic acid, ampicillin, piperacillin ± tazobactam, imipenem,
vancomycin and teicoplanin were determined by the Etest
method (BMD, Marne-la-Valle´e, France).
PCR
Glycopeptide-resistant enterococci were tested for the pres-
ence of the vanA and vanB resistance genes by PCR. DNA was
extracted by the boiling method of Elaichouni et al. [17]. PCR
assays were performed as described by Dutka-Malen et al. [18].
Two different primer pairs (vanA, vanB) [18] were used in the
assay (50 pmol of each individual primer/reaction, with initial
denaturation at 92 C for 2 min, followed by 30 cycles of 1 min
at 92 C, 1 min at 54 C and 1 min at 72 C. Amplicons were
analysed by electrophoresis on agarose 1% w/v gels with a
DNA ladder (Life Technologies, Gaithersburg, MD, USA) used
as a size standard. E. faecium BM4147 (vanA) and E. faecium
V583 (vanB) were used as reference strains. Gels were stained
with ethidium bromide.
Genotyping
Genomic DNA digested with SmaI was subjected to PFGE, as
described by Murray et al. [19,20] using a clamped homo-
geneous electric-field apparatus (CHEF-DRIII; Bio-Rad, Her-
cules, CA, USA). Samples of SmaI-restricted Staphylococcus
aureus NCTC 8325 DNA were included in each run as an
internal standard. Electrophoretic restriction patterns were
analysed by scanning photographic negatives. GelCompar
software was used for cluster analysis (Applied Maths
Kortrijk, Belgium) with the Dice correlation coefficient, and
a dendrogram was produced using the UPGMA (unweighted
pair group method using arithmetic averages) clustering
algorithm. Major restriction patterns were defined as patterns
differing by more than six fragments [21], and were each
designated with a number, with each variant indicated by a
suffix letter. Epidemic patterns were defined as patterns
corresponding to isolates from more than two patients.
Unique patterns were defined as patterns corresponding to
only one isolate.
Epidemiological data and definitions
Data were recorded concerning the ward (type of ward and
number of patients admitted) and the patient (age, sex,
previous hospital admissions, duration of hospital stay
and antibiotic treatment in the 7 days preceding strain
isolation). All the enterococci included in the study were from
clinical specimens, but isolates from stool samples were
excluded. No clinical information was collected to differentiate
colonisation from true infections, as the objective of the study
was centred on the frequency of resistance to amoxycillin and
not on the virulence of strains.
The main outcome was the incidence of Enterococcus
colonisation or infection. Crude incidence was estimated by
dividing the total number of cases of Enterococcus colonisation
or infection by the total number of exposed patients. The time
required for colonisation or infection by E. faecalis and E. faecium
strains, and for AmSE and AmRE strains was compared.
Risk factors
Two multivariate cohort analyses were performed to identify
risk factors for colonisation or infection with E. faecium (the
control cohort contained patients colonised or infected with
Entercoccus faecalis), and for colonisation or infection with
amoxycillin-resistant E. faecium strains (with the control cohort
being patients colonised or infected with E. faecium strains
susceptible to amoxycillin). The potential risk factors studied
were: sex, age, origin of the patient (transfer from another
hospital), ward in which the patient was hospitalised, duration
of hospitalisation before colonisation or infection, and antibi-
otic therapy before colonisation or infection. Previous antibiotic
treatment was first analysed as a factor in itself and was then
analysed according to the agent used.
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Odds ratios were estimated from regression coefficients and
95% confidence intervals (CIs) were calculated. The v2 test was
used to test correlations between variables, with p < 0.05
significant. To adjust for confounding factors, variables with
p values between 0.05 and 0.1 in univariate analyses were
added to multiple regression models. Statistical analysis was
performed using the Epi-Info and BMDP software packages.
R E S U L T S
Incidence
During the study, 24 228 patients were admitted to
the hospital for a total of 150 111 days. In total, 799
cases of Enterococcus colonisation or infection were
observed in 737 patients, giving crude incidences of
colonised or infected patients and of colonisation or
infection of 3.04% and 3.30%, respectively, and a
crude incidence of colonisation or infection of
5.32/1000 days of hospitalisation. Of these 799
cases of colonisation or infection, 69 involved
E. faecium strains in 67 patients. All 32 strains
showing resistance to amoxycillin were E. faecium
strains, accounting for 46.4% of the E. faecium
strains. This gave crude incidences of 0.46/1000
patient-days for all E. faecium strains (from 0.43 to
0.51 according to the period) and 0.21/1000 patient-
days for AmRE (from 0.19 to 0.24 according to the
period). Table 1 shows the distribution of cases
according to ward and to sites of colonisation or
infection. The incidence of E. faecium colonisation or
infection differed considerably between wards
(p < 10)5), whereas no difference was observed in
the frequency of amoxycillin resistance.
Resistance
None of the AmRE strains produced a b-lacta-
mase. The MICs of various b-lactam antibiotics
are shown in Table 2. Table 3 shows the fre-
quency of co-resistance in AmRE and AmSE
isolates, and compares these values to the fre-
quency of resistance in E. faecalis isolates. Only
one E. faecium isolate was resistant to vancomycin
(MIC > 256 mg ⁄L) and teicoplanin (MIC >
256 mg ⁄L) and was identified as the vanA type
by PCR. This strain was co-resistant to amoxycil-
lin, kanamycin, erythromycin and co-trimoxazole.
Molecular epidemiology
The 69 E. faecium isolates typed yielded 37 major
DNA patterns: 29 unique patterns (each asso-
ciated with one patient), five patterns corres-
ponding to two isolates, and three epidemic
patterns. Thirty major DNA patterns were iden-
tified among the 37 amoxycillin-susceptible iso-
Table 1. Distribution of cases of colonisation or infection
with Enterococcus faecium
Colonisation or infection
with E. faecium
Colonisation or infection
with E. faecium strains
showing resistance to
amoxycillin
Number
(frequencya) Incidenceb
Number
(frequencyc) Incidenceb
Wards
Haematology 15 (17.9) 2.54 7 (46.7) 1.18
Urology 7 (6.9) 1.35 4 (57.1) 0.77
Intensive care 9 (12.0) 2.00 5 (55.5) 1.11
Paediatric 4 (7.7) 0.80 3 (75.0) 0.60
Other medical
wards (N ¼ 14)
20 (7.5) 0.29 8 (40.0) 0.11
Other surgical
wards (N ¼ 10)
14 (6.4) 0.23 5 (35.7) 0.08
Sites of isolation
Urinary tract 47 (8.7) 0.31 23 (48.9) 0.15
Pus 3 (6.8) 0.02 2 (66.7) 0.013
Bloodstream 1 (8.3) 0.007 0 (0.0) 0.00
Bronchopulmonary tract 1 (7.7) 0.007 0 (0.0) 0.00
Other 17 (9.1) 0.11 7 (41.2) 0.05
aFrequency in the Enterococcus genus (%); bIncidence ⁄ 1000 patient-days; cFrequency
in E. faecium (%).
Table 2. MICs (mg/L) of various
b-lactam antibiotics for AmSE and
AmSE isolates E. faecium
isolates
b-lactam tested
Penicillin Ampicillin Amoxycillin
Amoxycillin/
clavulanate Piperacillin
Piperacillin/
Tazobactam Imipenem
AmSE (n ¼ 37)
Mean MIC 8.07 1.06 0.74 0.73 17.18 13.88 7.91
SD 18.62 1.33 0.78 0.87 29.91 21.96 12.73
MIC50 2 0.5 0.5 0.38 6 6 0.75
MIC90 16 2 1.5 1.5 32 32 > 32
Range 0.016–96 0.032–6 0.032–3 0.032–4 0.38–128 0.38–96 0.047 – > 32
AmRE (n ¼ 32)
Mean MIC 247.80 59.90 26.15 29.70 > 256 > 256 > 32
SD 37.71 65.73 22.15 41.54 0 0 0
MIC50 > 256 32 16 16 > 256 > 256 > 32
MIC90 > 256 128 64 48 > 256 > 256 > 32
Range 48 – > 256 16 – > 256 8–96 6 – > 96 > 256 > 256 > 32
AmSE, amoxycillin-susceptible Enterococcus; AmRE, amoxycillin-resistant Enterococcus; SD, standard deviation.
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lates, and seven among the 32 AmRE isolates.
Twenty-eight AmRE isolates and two AmSE had
epidemic patterns, and three AmRE isolates and
26 AmSE had unique patterns (one AmRE and
nine AmSE isolates had patterns corresponding
to two isolates) (relative risk: 16.19; 95% CI:
4.18–62.71). Some DNA patterns were shared by
isolates with different antibiotic susceptibility
phenotypes. Three major epidemic patterns com-
prised 21 (19 AmRE and two AmSE), six AmRE
and three AmRE isolates, respectively. AmRE
isolates were from different wards and different
periods of the study and the respective coloni-
sation or infection events occurred during and
after the first 48 h following admission (Fig. 1).
The vanA isolate belonged to an epidemic pat-
tern comprising 21 isolates with six different
antibiotic susceptibility phenotypes (susceptible,
AmSE-HLGR-HLKR-vancomycinS, AmRE-Low-
level GR (LLGR)-Low-level KR (LLKR)-vanc-
omycinS, AmRE-HLGR-HLKR-vancomycinS, AmRE-
LLGR-HLKR-vancomycinS, AmRE-LLGR-HLKR-
vancomycinR). The frequency of isolates yielding
epidemic patterns did not differ significantly
between haematology wards (56.3%) and other
wards (39.6%) (relative risk: 1.67; 95% CI:
0.70–3.97).
Clinical epidemiology
Clinical records were available for the 67 patients
colonised or infected with E. faecium and for 567
of the 737 patients colonised or infected with
E. faecalis (Table 4). The variables associated
significantly with E. faecium colonisation or infec-
tion in both univariate and multivariate analyses
are listed in Table 5. The risk of colonisation or
infection with E. faecium was higher if the patient
was hospitalised in a haematology ward or
treated with cephalosporins. None of the charac-
teristics studied were associated significantly with
infection with AmRE isolates after univariate
analysis; therefore multivariate analysis was not
performed.
D I S C U S S I O N
The frequency of amoxycillin resistance amongst
enterococci in our institution was very high, as
has also been reported in other countries (20%–
90%) [9–11]. The study design, based on 1-month
periods of surveillance every 6 months, facilitated
Table 3. Frequency of co-resistance
amongst enterococci
E. faecium isolates Total Enterococcus isolates
AmSE
(n ¼ 37)
n (%)
AmRE
(n ¼ 32)
n (%) RRa p
E. faecalis
(n ¼ 669)
n (%)
E. faecium
(n ¼ 69)
n (%) RRa p
Gentamicinb 5 (13.5) 5 (15.6) 1.16 NS 49 (7.0) 10 (14.5) 2.07 0.025
Kanamycinb 17 (45.9) 27 (84.4) 1.84 0.0009 382 (54.6) 44 (63.8) 1.17 NS
Erythromycin 32 (86.5) 32 (100) 1.16 NS 566 (81.0) 64 (92.7) 1.15 0.015
Chloramphenicol 14 (37.8) 19 (59.4) 1.57 NS 401 (57.4) 33 (47.8) 0.83 NS
Tetracycline 20 (54.1) 30 (93.7) 1.73 0.0002 521 (74.5) 50 (72.5) 0.97 NS
aRR, relative risk; bHigh-level.
Fig. 1. DNA fragment pattern similarity and epidemio-
logical information for Enterococcus faecium isolates (pat-
terns differing by more than six fragments). aAmRE,
amoxycillin-resistant Enterococcus; bColonisation or infec-
tion acquired after the first 48 h of hospitalisation; cN,
number of hospital-acquired (nosocomial); n, number of
hospital units or wards.
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the collection and the analysis of data and strains
in real time, but may misdiagnose outbreaks and
either overestimate or underestimate the fre-
quency of resistance. In the present study, no
significant differences were observed over the
3-year study period, thereby, establishing the
validity of the high frequency of resistance
observed. Moreover, this frequency of amoxycil-
lin resistance among E. faecium isolates did not
differ between wards (Table 1) or according to the
time of acquisition (Table 4). Thus, it is not
necessary to take into account the time of acqui-
sition, or the type of ward, when deciding how to
treat infections. Analysis of strains expressing
very high levels of amoxycillin resistance, as in
this study, suggests that the increase in resistance
is caused by mutations decreasing the binding
affinity of PBP5 for amoxycillin. This also results
in high-level resistance to other major b-lactam
antibiotics, such as piperacillin, amoxycillin ± cla-
vulanate and imipenem (Table 2) [22]. Such
high-level resistance to b-lactams may pose prob-
lems in terms of treatment, especially if, as
frequently observed (Table 3), it is associated
with high-level resistance to aminoglycosides.
In this study, the frequency of resistance to
imipenem and to piperacillin was higher than that
of resistance to amoxycillin; i.e., amoxycillin-
susceptible strains exhibited resistance to pip-
eracillin and imipenem. Rybkine et al. [22]
demonstrated that MICs of ampicillin were lower
than those of piperacillin and imipenem; simi-
larly, El Amin et al. in a Swedish hospital [23] and
Brandt et al. in Switzerland [24] described resist-
ance to imipenem in ampicillin-susceptible
strains. The observed difference between MICs
of amoxycillin and MICs of amoxycillin-clavula-
nate was probably explained by the higher sat-
uration of PBP5 by the combination [22].
The high prevalence of AmRE isolates in our
hospital was caused partly by clonal spread of
E. faecium strains, since >85% of AmRE isolates
shared three PFGE patterns (Fig. 1). Isolates
acquired after the first 48 h of hospitalisation
were observed with identical patterns throughout
the study, suggesting long-term transmission
within the hospital, as demonstrated in the study
of Fortu´n et al. [25]. However, there was also
evidence for the clonal dissemination of some
epidemic strains out of our hospital since the
prevalence of AmRE strains was no lower among
isolates responsible for colonisations or infections
acquired during the first 48 h than among colo-
nisations or infections acquired after 48 h of
hospitalisation. However, the classification of
cases does not exclude the possibility that patients
could have acquired AmRE during a previous
hospital stay.
An association between the use of antibiotics,
such as extended-spectrum cephalosporins, and
infection with enterococci, particularly AmRE, has
been reported in different studies [25–30]. The
methodology used in some studies [26,27] may
have led to the identification of cephalosporins as
a risk factor for AmRE by chance because the cases
(patients infected with AmRE) were compared to
patients without Enterococcus infection. Therefore,
Table 4. Main characteristics of patients included in the
study
Colonisation or infection with
E. faecalis
(n ¼ 567)
n (%)
E.faecium
(n ¼ 67)
n (%)
AmSEa
(n ¼ 36)
n (%)
AmREa
(n ¼ 31)
n (%)
On admission
Age, yrsb 52 (25) 49 (26) 53 (25) 46 (28)
Men 282 (49.7) 29 (43.3) 17 (47.2) 12 (38.7)
Transfer from another hospital 61 (10.8) 3 (4.5) 1 (2.8) 2 (6.5)
During hospitalisation
Colonisation or infection
Acquiredc 351 (61.9) 45 (67.2) 23 (63.9) 22 (71.0)
Delay to acquisition (days)b 9.9 (14.8) 14.1 (18.9) 15.8 (23.4) 12.0 (12.0)
Ward
Haematology 49 (8.6) 14 (20.9) 8 (22.2) 6 (19.4)
Urology 80 (14.1) 7 (10.4) 3 (8.3) 4 (12.9)
Intensive care 56 (9.9) 9 (13.4) 4 (11.1) 5 (16.1)
Paediatric 34 (6.0) 4 (6.0) 1 (2.8) 3 (9.7)
Other medical wards 185 (32.7) 21 (31.3) 12 (33.3) 9 (29.0)
Other surgical wards 163 (28.7) 12 (17.9) 8 (22.2) 4 (12.9)
Antimicrobial therapy
No antibiotic 444 (78.3) 39 (58.2) 21 (58.3) 18 (58.1)
Penicillin 46 (8.1) 5 (7.5) 3 (8.3) 2 (6.5)
Cephalosporin 43 (7.6) 20 (29.9) 10 (27.8) 10 (32.5)
Fluoroquinolone 26 (4.6) 4 (6.0) 4 (11.1) 0 (0)
Aminoglycoside 28 (4.9) 8 (11.9) 3 (8.3) 5 (16.1)
Metronidazole 19 (3.4) 7 (10.4) 6 (19.4) 1 (3.2)
aAmSE, amoxycillin-susceptible Enterococcus faecium; AmRE, amoxycillin-resistant
Enterococcus faecium.
bFor continuous variables, mean values (± standard errors) are given.
cColonisation or infection acquired after the first 48 h of hospitalisation.
Table 5. Univariate and multivariate analyses of factors
associated with Enterococcus faecium colonisation or infection
Risk factor
Univariate analysis
Multivariate
analysis
Odds Ratio CI 95%a Odds Ratio CI 95%a
Prior administration of antibiotics 2.56 1.52–4.32 NS –
Cephalosporins 5.11 2.79–9.33 5.05 2.74–9.31
Aminoglycosides 2.66 1.16–6.08 NS –
Metronidazole 3.21 1.31–7.85 NS –
Hospitalisation in
a haematology ward
2.61 1.36–5.00 2.55 1.30–5.02
aCI 95%, 95% confidence interval.
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two risk factor analyses were conducted, first to
identify significant factors for colonisation or
infection with E. faecium, and second to identify
significant factors for colonisation or infection
with AmRE. In our study, two previously identi-
fied risk factors for E. faecium bacteraemia [31]
were linked significantly with colonisation or
infection with E. faecium: namely previous admin-
istration of cephalosporins (relative risk of 5) and
hospitalisation in a haematology unit (relative risk
of 2.5). Fortu´n et al. [25] identified previous
administration of b-lactams as a risk factor for
bacteraemia with AmRE, comparing patients
infected with AmRE to patients infected with
AmSE. In contrast, no risk factor was identified as
significantly associated with colonisation or infec-
tion with AmRE in the present study. First,
gastrointestinal carriage of enterococci is frequent
and previous carriage of the resistant strain cannot
be excluded [26]. Second, the AmRE isolates were
co-resistant to non-b-lactam antibiotics (Table 3).
So, all antibiotic treatment, other than broad-
spectrum penicillins, reduces the power of the
analysis. However, it is clear that the selective
pressure exerted by all antibiotics except glyco-
peptides favoured the isolation of these strains.
Moreover, AmRE clones have a considerable
potential to disseminate, as demonstrated by the
high frequency of isolates yielding epidemic pat-
terns.
Vancomycin resistance does not seem to be a
major problem in our hospital at present,
although multiresistant enterococci are endemic.
Total vancomycin consumption is lower in our
hospital than in American hospitals, but vanco-
mycin consumption is high in haematology
wards, in which the incidence of AmRE colonisa-
tion or infection is also high [32]. In these wards,
once the vanA gene appears on a plasmid, its
dissemination is encouraged by increasing use of
glycopeptides and of other antibiotics. It would
therefore be of value to perform a prospective
survey of clinical isolates of E. faecium in our
hospital.
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